123 related articles for article (PubMed ID: 31547956)
1. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
2. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract][Full Text] [Related]
3. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
[TBL] [Abstract][Full Text] [Related]
4. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
5. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
[TBL] [Abstract][Full Text] [Related]
6. A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.
Wang K; Li J; Xiong YF; Zeng Z; Zhang X; Li HY
Sci Rep; 2018 Feb; 8(1):3179. PubMed ID: 29453409
[TBL] [Abstract][Full Text] [Related]
7. Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Nguyen D; Yu J; Reinhold WC; Yang SX
JAMA Netw Open; 2020 Jul; 3(7):e207213. PubMed ID: 32644137
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Miyazaki N; Iwasaki T; Sakai H; Watanuki R; Tanizawa Y; Cai Z; Kawaguchi T; Tsurutani J; Nagashima K
Curr Med Res Opin; 2024 May; 40(5):827-837. PubMed ID: 38597173
[TBL] [Abstract][Full Text] [Related]
9. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK; Dasgupta A; Sotgia F; Mercier I; Pestell RG; Sabel M; Kleer CG; Brody JR; Lisanti MP
Am J Pathol; 2009 Jun; 174(6):2023-34. PubMed ID: 19411448
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer.
Luo C; Zhong X; Fan Y; Wu Y; Zheng H; Luo T
Breast; 2022 Jun; 63():24-28. PubMed ID: 35279509
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.
Zhang M; Zhang S; Wen Y; Wang Y; Wei Y; Liu H; Zhang D; Su J; Wang F; Zhang Y
PLoS One; 2015; 10(11):e0142279. PubMed ID: 26550991
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels.
Lee SY; Yoo TK; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Lee SB
Breast Cancer Res Treat; 2023 Jul; 200(1):47-61. PubMed ID: 37184775
[TBL] [Abstract][Full Text] [Related]
14. Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
Bergeron A; Bertaut A; Beltjens F; Charon-Barra C; Amet A; Jankowski C; Desmoulins I; Ladoire S; Arnould L
Br J Cancer; 2023 Jul; 129(1):122-134. PubMed ID: 37120672
[TBL] [Abstract][Full Text] [Related]
15. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study.
Hall P; Ploner A; Bjöhle J; Huang F; Lin CY; Liu ET; Miller LD; Nordgren H; Pawitan Y; Shaw P; Skoog L; Smeds J; Wedrén S; Ohd J; Bergh J
BMC Med; 2006 Jun; 4():16. PubMed ID: 16813654
[TBL] [Abstract][Full Text] [Related]
16. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
O'Brien SL; Fagan A; Fox EJ; Millikan RC; Culhane AC; Brennan DJ; McCann AH; Hegarty S; Moyna S; Duffy MJ; Higgins DG; Jirström K; Landberg G; Gallagher WM
Int J Cancer; 2007 Apr; 120(7):1434-43. PubMed ID: 17205517
[TBL] [Abstract][Full Text] [Related]
17. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT; Kim H; Whitman A; Spanheimer PM
Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.
Tsang JY; Ho CS; Ni YB; Shao Y; Poon IK; Chan SK; Cheung SY; Shea KH; Marabi M; Tse GM
Cancer Immunol Immunother; 2020 May; 69(5):799-811. PubMed ID: 32055918
[TBL] [Abstract][Full Text] [Related]
19. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
20. A Novel Neoplastic Fusion Transcript,
Liu CC; Veeraraghavan J; Tan Y; Kim JA; Wang X; Loo SK; Lee S; Hu Y; Wang XS
Clin Cancer Res; 2021 Feb; 27(3):785-798. PubMed ID: 33172895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
